Published in Cancer Weekly, March 14th, 2000
A study presented at the 22nd Annual San Antonio Breast Cancer Symposium by researchers from the University of Vienna indicates that this therapy is significantly more effective than cyclophosphamide/methotrexate/5-fluorouracil (CMF) chemotherapy.
Patients were chosen at random to receive either...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.